Peptides›Metabolic›SLU-PP-332

SLU-PP-332

/ Estrogen-related receptor (ERR) agonist (small molecule)

TIER 3 · PreclinicalN = 0 · TESTING PENDING

ALIAS · SLU-PP-332

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Estrogen-related receptor (ERR) agonist (small molecule)CATEGORY · Metabolic

Tier 3. Estrogen-related receptor (ERR) pan-agonist small molecule developed in academic medicinal-chemistry programs (Saint Louis University / Scripps). Rodent metabolic and exercise-mimetic data; no human Phase 1 trial published as of early 2026.

§ B · Mechanism of action

SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors ERR-alpha, ERR-beta, and ERR-gamma - orphan nuclear receptors that share structural homology with the estrogen receptor but do not bind estradiol. ERRs partner with PGC-1alpha to transcriptionally regulate mitochondrial biogenesis, oxidative phosphorylation gene programs, and the metabolic adaptations of exercise. Rodent administration of SLU-PP-332 has been reported to recapitulate components of the exercise transcriptional response in skeletal muscle without exercise itself, framing the molecule within the 'exercise mimetic' pharmacological category alongside AICAR and SR9009.

§ C · Human clinical evidence

Tier 3. Patch 2011 (J Med Chem) described medicinal-chemistry development of ERR-targeting ligands in the Burris laboratory. Subsequent Billon publications reported rodent in-vivo characterisation of SLU-PP-332 in obesity and exercise paradigms, with reports of increased running endurance, reduced adiposity, and improved metabolic parameters in diet-induced-obese mice. No human study.

§ D · Primary literature

PubMed21218783Patch RJ et al. — Identification of diaryl ether-based ligands for estrogen-related receptor alpha as potential antidiabetic agents · Journal of Medicinal Chemistry · in-vitroMedicinal-chemistry program identifying diaryl-ether ERR-alpha agonists with cellular activity and metabolic-pathway pharmacodynamics; predecessor chemistry to later SLU-PP series.Limitations: In-vitro and cellular assays; chemistry-development paper without in-vivo efficacy.2011

§ F · Safety signal

No human safety database. ERR-pathway activation overlaps with broad metabolic and mitochondrial transcriptional programs; off-target consequences of chronic pan-ERR activation in humans are unstudied.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

Vendor sale of SLU-PP-332 as a research-grade exercise mimetic relies entirely on rodent data from the originating laboratories. No independent replication of the in-vivo metabolic and endurance findings has been published. The 'exercise mimetic' framing repeats a claim that has been made for several molecules (AICAR, SR9009, GW501516) and has not yet translated to an approved human therapeutic in this class.